Aktie A1T9FK PORTOLA PHARMACEUTICALS, INC.
Zu einer Liste hinzufügen
Um diese Funktionalität nutzen zu können, müssen Sie Mitglied sein
EinloggenRegistrieren
Inaktiver Wert

Andere Sprachen Portola Pharmaceuticals, Inc.

Aktien

A1T9FK

US7370101088

Andere Sprachen

Suchen
Ergebnisse ansehen
Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!
100% kostenlose Registrierung
PORTOLA PHARMACEUTICALS INC : Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Material Modification to Rights of Security Holders, Changes in Control or Registrant, Change in Directors or Principal Officers, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits (form 8-K)
Portola Pharmaceuticals, Inc.(NasdaqGS:PTLA) dropped from S&P Biotechnology Select Industry Index
Portola Pharmaceuticals, Inc.(NasdaqGS:PTLA) dropped from S&P TMI Index
Portola Pharmaceuticals, Inc.(NasdaqGS:PTLA) dropped from S&P Global BMI Index
Alexion Pharmaceuticals, Inc. completed the acquisition of the remaining 96.6% stake in Portola Pharmaceuticals, Inc..
Portola Pharmaceuticals : Amendment to a previously filed SC TO-T
Portola Pharmaceuticals : Amendment to a previously filed SC 14D9
PORTOLA PHARMACEUTICALS INC : Other Events (form 8-K)
Portola Pharmaceuticals, Inc. Receives Written Notice of Termination from Bayer AG
PORTOLA PHARMACEUTICALS INC : Submission of Matters to a Vote of Security Holders (form 8-K)
Portola Pharmaceuticals : Announces Virtual 2020 Annual Stockholder Meeting
Portola Pharmaceuticals : U.S. Centers for Medicare and Medicaid Services Proposes Extending New Technology Add-on Payment Reimbursement
Portola Pharmaceuticals : U.S. Centers for Medicare & Medicaid Services (CMS) Proposes Extending New Technology Add-on Payment (NTAP) Reimbursement for Portola Pharmaceuticals' Andexxa® for Third Year
PORTOLA PHARMACEUTICALS : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-Q)
Portola Pharmaceuticals: 1Q Earnings Snapshot
Portola Pharmaceuticals : Reports First Quarter 2020 Financial Results and Provides Corporate Update
Portola Pharmaceuticals, Inc. Suspends Prior Guidance for Approximately 350 New Hospital Adds in 2020
Portola Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2020
PORTOLA PHARMACEUTICALS INC : Entry into a Material Definitive Agreement, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits (form 8-K)
WeissLaw LLP Investigates Portola Pharmaceuticals, Inc.
Keine Ergebnisse zu dieser Suche
Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Filter

Suchen

Datum der Veröffentlichung

Vom

Bis

  1. Börse
  2. Aktien
  3. A1T9FK Aktie
  4. Nachrichten Portola Pharmaceuticals, Inc.
  5. Andere Sprachen